Corticotropin-Releasing Hormone
Showing 26 - 50 of 6,286
Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian
Not yet recruiting
- Hormone-receptor-positive Breast Cancer
- +3 more
- Aromatase inhibitor
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023
(Dyadic Adjustment) on Quality of Life of Prostate Cancer With
Completed
- Prostate Cancer
- Gonadotropin-releasing Hormone (GnRH) agonist therapy
-
Paris, FranceIpsen Central Contact
Dec 3, 2021
Diminished Ovarian Reserve Trial (Dydrogesterone priming ovarian stiumulation protocol, GnRH antagonist protocol)
Not yet recruiting
- Diminished Ovarian Reserve
- Dydrogesterone priming ovarian stiumulation protocol
- GnRH antagonist protocol
- (no location specified)
Apr 26, 2023
Radiotherapy and Androgen Deprivation In Combination After Local
Not yet recruiting
- Prostate Cancer
- Luteinising Hormone-Releasing Factor Analogue
- (no location specified)
Nov 16, 2023
Coronary Artery Bypass Grafting, Remimazolam Trial in Yangzhou (Remimazolam, midazolam)
Recruiting
- Coronary Artery Bypass Grafting
- Remimazolam
-
Yangzhou, Jiangsu, ChinaThe Affiliated Hospital of Yangzhou University.
Jun 5, 2023
Prostate Cancer With =10 Bone Metastases Trial (Apalutamide, 89Sr, Luteinizing Hormone-Releasing Hormone Analog)
Not yet recruiting
- Prostate Cancer With ≤10 Bone Metastases
- Apalutamide
- +2 more
- (no location specified)
Feb 22, 2023
Infertility, IVF, Preimplantation Diagnosis Trial in Barcelona (GnRh antagonist, Micronized progesterone)
Recruiting
- Infertility
- +2 more
- GnRh antagonist
- Micronized progesterone
-
Barcelona, Catalunya, SpainInstitut Universitari Dexeus
Mar 29, 2022
Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)
Not yet recruiting
- Prostate Cancer
- DFMO
- +3 more
-
Baltimore, MarylandJohns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
Sep 22, 2023
Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor
Not yet recruiting
- Androgen Deprivation Therapy
- +4 more
- Gonadotropin-Releasing Hormone Agonist
- +2 more
- (no location specified)
Jan 18, 2023
Prostate Adenocarcinoma Trial in Duarte (drug, radiation, other)
Recruiting
- Prostate Adenocarcinoma
- Leuprolide Acetate
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 14, 2022
Prostate Cancer, Stage IV Prostate Cancer Trial in Tampa (Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel)
Recruiting
- Prostate Cancer
- Stage IV Prostate Cancer
- Luteinizing Hormone Releasing Hormone
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Jun 1, 2022
Infertility Trial in Istanbul (Gonadotropin releasing hormone antagonist (Cetrotide), Medroxyprogesterone Acetate (Tarlusal),
Not yet recruiting
- Infertility
- Gonadotropin releasing hormone antagonist (Cetrotide)
- +2 more
-
Istanbul, TurkeyBezmialem Vakif University
Mar 13, 2023
Functional Dyspepsia Trial in Kansas City (Acthrel)
Withdrawn
- Functional Dyspepsia
-
Kansas City, MissouriChildren's Mercy Hospital and Clinics
May 15, 2019
Infertility, ART Trial in Shanghai (Duphaston, Cetrorelix)
Recruiting
- Infertility
- ART
-
Shanghai, ChinaShangHai JIAI Genetics&IVF Institute
Mar 28, 2022
Hypogonadotropic Hypogonadism Trial in Boston (kisspeptin 112-121, GnRH)
Recruiting
- Hypogonadotropic Hypogonadism
- kisspeptin 112-121
- GnRH
-
Boston, MassachusettsMassachusetts General Hospital
Jun 29, 2022
Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Polycystic Ovarian Syndrome Trial (GnRH antagonist, MPA)
Not yet recruiting
- Preimplantation Genetic Testing
- +3 more
- GnRH antagonist
- MPA
- (no location specified)
Apr 9, 2022
Endometriosis, Adenomyosis, Infertility, Female Trial in Suresnes (GnRH agonist)
Recruiting
- Endometriosis
- +2 more
- GnRH agonist
-
Suresnes, FranceHopital Foch
Aug 2, 2022
Hypogonadism Trial in Denver (Acyline, Placebo Gel, Placebo Tablet)
Recruiting
- Hypogonadism
- Acyline
- +4 more
-
Denver, ColoradoUniversity of Colorado CCTSI CTRC
Apr 25, 2022
Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)
Not yet recruiting
- Breast Cancer
- Pyrotinib
- +7 more
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Dec 2, 2022
IVF Trial in Shanghai (Gonadotrophin releasing hormone antagonist protocol, Progestin-primed ovarian stimulation protocol)
Not yet recruiting
- IVF
- Gonadotrophin releasing hormone antagonist protocol
- Progestin-primed ovarian stimulation protocol
-
Shanghai, ChinaShanghai first Maternity and Infant health hospital, Tong Ji Uni
Aug 3, 2021
Intestinal Barrier Dysfunction Trial in London (Vagal nerve stimulation)
Completed
- Intestinal Barrier Dysfunction
- Vagal nerve stimulation
-
London, United KingdomThe Wigate Institute, Barts and the London School of Medicine an
Mar 7, 2022
Endometrial Tumors, Atypical Endometrial Hyperplasia, Progesterone Resistance Trial in Shanghai (GnRHa, Letrozole 2.5mg,
Recruiting
- Endometrial Neoplasms
- +2 more
- GnRHa
- +3 more
-
Shanghai, Shanghai, ChinaObstetrics and Gynecology Hospital, Fudan University
Jul 29, 2022
FSGS, Renal Transplantation, Kidney Transplantation Trial in Chapel Hill (Acthar)
Withdrawn
- FSGS
- +2 more
-
Chapel Hill, North CarolinaUniversity of North Carolina at Chapel Hill
Aug 26, 2021
Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles Trial in Assiut (Effect of adding gonadotropins
Recruiting
- Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles
- Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial
-
Assiut, EgyptMedicine
May 11, 2022